ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Aug 05, 2021 11:45 JST
Source:
Eisai
Eisai Receives Award for Excellence in Corporate Communications at the 37th Corporate Communications Awards
TOKYO, Aug 05, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received the Award for Excellence in Corporate Communications at the 37th annual Corporate Communications Awards, hosted by the Japan Institute for Social and Economic Affairs, an affiliate of the Japanese Business Federation (Tokyo).
The Corporate Communications Awards were established in 1984 with the aim of advancing the field by recognizing companies and individuals that practice excellent corporate communications. There are three awards: the Award for Excellence in Corporate Communications, Outstanding Leadership Awards in Corporate Communications, and the Outstanding Merit Awards.
The Award for Excellence in Corporate Communications received by Eisai is given to the company that contribute to society by identifying what is expected and required of them by society, reflecting this in their management, and disseminating and communicating accurate information about their corporate activities to their stakeholders through public relations initiatives.
The award was presented to Eisai in recognition of its efforts to promote understanding of dementia, which has become a social issue, by providing not only information on the status of new drug development, but also on the latest findings on the pathological condition of the disease and the social burden of nursing care, as well as efforts to promote understanding among stakeholders through study sessions for scientific and medical journalists and providing easy-to-understand explanations of difficult science, thereby making a significant contribution to increase the benefits of patients and their families in line with its corporate philosophy of human health care (hhc).
Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides, and Eisai calls this philosophy the "human health care (hhc)" philosophy, in one word. In the new medium-term business plan "EWAY Future & Beyond" started in FY2021, based on the hhc philosophy, Eisai aims to remove the anxiety of "The People", including not only patients but also society at large, by delivering not only pharmaceutical products but also solutions to The People. In order to realize the hhc philosophy, we will make further contributions to increase the benefits to "The People" by enhancing corporate value through public relations activities.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Mitsubishi Shipbuilding Receives Order from the University of Tokyo for "MiPoLin" Power Prediction and Lines Selection System
Mar 28, 2024 16:45 JST
Mitsubishi Logisnext Completes Demonstration of Automated Truck Loading, Leading to Start of Actual Operations in Japan
Mar 28, 2024 13:52 JST
Toyota Releases Sales, Production, and Export Results for February 2024
Mar 28, 2024 13:35 JST
TANAKA to Install 500 kW Fuel Cell System to Promote the Use of Hydrogen Energy at Production Plants
Mar 28, 2024 03:00 JST
PEVE to change name to TOYOTA BATTERY Co., Ltd. and produce batteries for a wide range of electric vehicles
Mar 27, 2024 15:13 JST
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy System
Mar 27, 2024 15:00 JST
TANAKA Holdings Announces Green Loan Financing for Construction of New Head Office Building
Mar 27, 2024 03:00 JST
JFE Steel and Hitachi Jointly Started Providing Solutions for the Steel Industry
Mar 26, 2024 19:04 JST
La Banque Postale and JCB join forces to elevate payments experience for travellers in France
Mar 26, 2024 15:00 JST
Fujitsu Tech Leverages AI and Underwater Drone Data for 'Ocean Digital Twin'
Mar 26, 2024 10:24 JST
NEC develops marketing strategy planning & effectiveness simulation technology using generative AI
Mar 25, 2024 10:08 JST
Toyota to Open New Tokyo Head Office in Shinagawa in FY2030
Mar 22, 2024 16:15 JST
Hitachi Selected as CDP Supplier Engagement Leader for the Third Consecutive Year
Mar 22, 2024 16:04 JST
Mitsubishi Motors Celebrates Production of 100,000th fully electric minivehicle
Mar 22, 2024 15:34 JST
JCB and AEON Credit Service Indonesia Launch the AEON JCB Precious Card
Mar 22, 2024 15:00 JST
JCB Issues White Paper on Calculating CO2 Emissions by Payment Method in Japan
Mar 22, 2024 12:00 JST
NEC and NTT successfully conduct first-of-its-kind long-distance transmission experiment over 7,000km using 12-core optical fiber
Mar 22, 2024 08:38 JST
Lifenet and Eisai Co-Develop Dementia Insurance "be"
Mar 21, 2024 17:36 JST
Toyota: Clarification of the Roles of and Expectations for Outside Executives, Revision of the Independence Assessment Criteria, and the Changes to Members of the Board of Directors and the Audit and Supervisory Board Members following the 120th Ordinary General Shareholders' Meeting
Mar 21, 2024 16:47 JST
Sales of Evolved GR Yaris to Start in April, While Purchasing Lotteries for WRC Driver-supervised Special Editions Start Today
Mar 21, 2024 16:31 JST
More Latest Release >>
Related Release
Lifenet and Eisai Co-Develop Dementia Insurance "be"
3/21/2024 5:36:00 PM JST
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
3/21/2024 4:10:00 PM JST
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
3/6/2024 5:47:00 PM JST
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
2/21/2024 3:26:00 PM JST
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
2/20/2024 9:35:00 AM JST
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
2/16/2024 9:31:00 AM JST
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
2/1/2024 6:04:00 PM JST
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis
1/26/2024 4:26:00 PM JST
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan
1/18/2024 3:12:00 PM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time
1/17/2024 5:08:00 PM JST
More Press release >>